Session » (0196–0228) Infection-related Rheumatic Disease Poster
- 9:00AM-11:00AM
-
Abstract Number: 0228
A Comprehensive Retrospective Analysis of Polymyalgia Rheumatica in Long COVID Patients at an Academic Medical Center in the Midwest
- 9:00AM-11:00AM
-
Abstract Number: 0202
Analysis of the Effects of Immunosuppressive Therapy on Herpes Zoster Events After Each of Three Doses of the BNT162b2 mRNA Vaccine in Patients with Spondyloarthritis (SpA)
- 9:00AM-11:00AM
-
Abstract Number: 0227
Associations of DMARDs with Post-Acute Sequelae of COVID-19 in Patients with Systemic Autoimmune Rheumatic Diseases: A Prospective Study
- 9:00AM-11:00AM
-
Abstract Number: 0225
Breakthrough SARS-Cov-2 Infection and Disease Flares in Patients with Rheumatoid Arthritis: Result from COVAD E-Survey Study
- 9:00AM-11:00AM
-
Abstract Number: 0205
Changes in Serum Rheumatoid Factor Following Eradication of Hepatitis C Virus Infection with Interferon or Direct Antiviral Therapy
- 9:00AM-11:00AM
-
Abstract Number: 0211
COVID-19 Outcome and Association to Anti-Spike Antibody Levels in Patients on Immunosuppressive Therapy; A Prospective Cohort Study
- 9:00AM-11:00AM
-
Abstract Number: 0214
COVID-19 Vaccine Uptake, Hesitancy, and Flare in a Large Rheumatology Practice Network
- 9:00AM-11:00AM
-
Abstract Number: 0197
Development of a Chikungunya Arthritis Disease Activity Score
- 9:00AM-11:00AM
-
Abstract Number: 0215
Effectiveness of Three Doses of SARS-CoV-2 Vaccines in Brazilian Patients with Systemic Vasculitides: Preliminary Results of a Real-life Prospective Cohort
- 9:00AM-11:00AM
-
Abstract Number: 0199
Experience in Real-World Conditions of the Effectiveness of the Vaccine Against Herpes Zoster Virus
- 9:00AM-11:00AM
-
Abstract Number: 0200
Herpes Zoster Prevalence in Patients with Rheumatic Diseases
- 9:00AM-11:00AM
-
Abstract Number: 0216
High Immunogenicity of mRNA Covid-19 Vaccine Booster in Immune Mediated Inflammatory Disease
- 9:00AM-11:00AM
-
Abstract Number: 0198
Improving Vaccination Uptake of Herpes Zoster in Young Rheumatic Disease Patients Ages 18-49 Using Specialty Pharmacy Partnership
- 9:00AM-11:00AM
-
Abstract Number: 0218
Incidence and Risk Factors for Breakthrough COVID-19 After Tixagevimab/Cilgavimab Among Patients with Systemic Autoimmune Rheumatic Diseases
- 9:00AM-11:00AM
-
Abstract Number: 0196
Limited Regulatory T Cell Response in Post-Chikungunya Viral Arthritis: A Therapeutic Opportunity?
- 9:00AM-11:00AM
-
Abstract Number: 0210
Longitudinal T Cell Responses to a Series of Four SARS-CoV-2 Vaccine Doses or COVID-19 in Patients on TNF Inhibitors
- 9:00AM-11:00AM
-
Abstract Number: 0220
Paxlovid (Nirmatrelvir Plus Ritonavir) in Patients with Underlying Rheumatological Diseases, in Preventing COVID-19 Related Hospitalization and Death
- 9:00AM-11:00AM
-
Abstract Number: 0208
Pneumocystis Jirovecii Pneumonia (PJP) Prophylaxis (PPX), Investigating the Practice Patterns of Providers for Patients on Chronic, High-Dose Immunosuppression in a Rural Integrated Health System
- 9:00AM-11:00AM
-
Abstract Number: 0221
Post-COVID-19 Autoimmune Serologies and Immunophenotypes
- 9:00AM-11:00AM
-
Abstract Number: 0222
Predictors of Adverse Prognosis Following Hospitalization for COVID-19 Infection in Patients with Immune Mediated Inflammatory Diseases Treated with Rituximab
- 9:00AM-11:00AM
-
Abstract Number: 0203
Projecting the Impact on Clinical Outcomes in ANCA-Associated Vasculitis of Delaying Retreatment with Rituximab for Vaccine Optimization
- 9:00AM-11:00AM
-
Abstract Number: 0226
Relationships Among Parameters of Mineral Metabolism and Bone Turnover During Acute COVID-related Hospitalization and Subsequent Follow Up: A Pilot Study
- 9:00AM-11:00AM
-
Abstract Number: 0224
Risk Factors and Outcomes for Repeat COVID-19 Infection Among Patients with Systemic Autoimmune Rheumatic Diseases: A Case-control Study
- 9:00AM-11:00AM
-
Abstract Number: 0206
Risk of Hepatitis B Virus Reactivation in Patients with Rheumatoid Arthritis Receiving JAK Inhibitor or IL-6 Inhibitor: A Systematic Review and Meta-Analysis
- 9:00AM-11:00AM
-
Abstract Number: 0204
Risk of Severe Infections Associated with Immunoglobulin Deficiency Under Rituximab Therapy in Immune Mediated Inflammatory Diseases
- 9:00AM-11:00AM
-
Abstract Number: 0207
Role of Pneumocystis Jirovecii Pneumonia Prophylaxis with Trimethoprim-Sulfamethoxazole Among Patients with Autoimmune Inflammatory Diseases Receiving High-Dose Glucocorticoids: A Systematic Review and Meta-Analysis
- 9:00AM-11:00AM
-
Abstract Number: 0219
Safety and Efficacy of Pre-Exposure Prophylaxis with Tixagevimab/Cilgavimab (Evusheld) in Patients with Autoimmune Diseases and Renal Involvement Who Received Rituximab
- 9:00AM-11:00AM
-
Abstract Number: 0217
Safety and Efficacy of Tixagevimab/Cilgavimab (Evusheld) in Autoimmune Inflammatory Rheumatic Disease Patients – a Prospective Multicenter Open-label Study
- 9:00AM-11:00AM
-
Abstract Number: 0209
Safety of Bivalent SARS-CoV-2 Vaccines as a Second Booster Dose in Arthritis Patients on Immunosuppressive Therapies
- 9:00AM-11:00AM
-
Abstract Number: 0223
Severity and Risk Factors of Hospitalization of Omicron in Patients with Rheumatoid Arthritis
- 9:00AM-11:00AM
-
Abstract Number: 0212
The Impact of Immunosuppression on the Humoral Immunogenicity of SARS-CoV-2 mRNA Vaccines in SLE